• Home

  • HEALTH CARE

  • HEALTHY LIFESTYLE

  • HYGIENE

  • COSMETICS

  • FOR HIM

  • PREGNANCY AND MOTHERHOOD

  • CHILD

    2. HEALTH CARE
    3. Anoro Ellipta, powder for inhalation dosed 55 mcg/22 mcg/dose in a powder inhaler 30 doses— Made in Great Britain — Free Delivery

    Anoro Ellipta, powder for inhalation dosed 55 mcg/22 mcg/dose in a powder inhaler 30 doses— Made in Great Britain — Free Delivery


    Brand: GlaxoSmithKline
    Product Code: Anoro Ellipta
    Availability: In Stock
    $54.22
    Add to Cart

    Product description

    Anoro Ellipta Inhalation Powder is indicated for supportive bronchodilator therapy to relieve symptoms in adult patients with chronic obstructive pulmonary disease (COPD).

    Compound

    Active ingredients: umeclidinium, vilanterol;
    1 dose delivered contains 55 mcg umeclidinium (bromide form) and 22 mcg vilanterol (triphenatate form) this corresponds to a pre-distributed dose of 74.2 mcg umeclidinium bromide and 25 mcg vilanterol (triphenatate form);
    Excipients: lactose monohydrate, magnesium stearate.

    Contraindications

    Hypersensitivity to active substances or to any of the excipients.

    Mode of application

    The preparation  Anoro Ellipta is intended for inhalation only.

    Application features

    Pregnant
    It should be used during pregnancy only if the expected benefit to the pregnant woman outweighs the potential risk to the fetus.
    Children
    Not applicable to children.
    Drivers
    Does not affect or has a slight effect on the ability to drive vehicles and operate machinery.

    Overdose

    An overdose of umeclidinium / vilanterol is likely to have signs and symptoms associated with the actions of the individual components, which are consistent with known adverse reactions of inhaled muscarinic antagonists (eg, dry mouth, visual disturbances and tachycardia) or reactions that have been observed with overdose of other beta 2 -adrenoceptor agonists (eg, arrhythmia, tremor, headache, tachycardia, nausea, hyperglycemia, and hypokalemia).
    In case of overdose, the patient's treatment should be symptomatic with appropriate monitoring if necessary.

    Side effects

    The most commonly reported adverse reaction with umeclidinium / vilanterol was nasopharyngitis (9%).

    Interaction

    Medicines containing beta-blockers can weaken or antagonize the effect of beta 2 -adrenergic agonists such as vilanterol. The simultaneous use of both non-selective and selective beta-blockers should be avoided, unless there is a compelling reason for their use.

    Storage conditions

    Store at a temperature not exceeding 25 ° C.
    Keep out of the reach of children.
    Store in original packaging to protect from moisture.
    Apply within 6 weeks after opening the tray.
    Shelf life - 2 years

    There are no reviews for this product.
    VEV Healthcare Store © 2017